Galenica Expands Horizons in the Pharmaceutical Industry
In a groundbreaking achievement, Moroccan pharmaceutical company Galenica has successfully dispatched its inaugural export to Russia, marking a significant milestone in the company’s history. This historic shipment, carried out in collaboration with Asia Pharm Group, signifies the first time a Moroccan, Arab, and African pharmaceutical laboratory has ventured into the Eurasian Economic Union market, which includes countries such as Russia, Armenia, Belarus, Kazakhstan, and Kyrgyzstan. This move is a testament to Galenica's commitment to expanding its global footprint and enhancing its product offerings.
The export follows Galenica's noteworthy accomplishment of becoming the first pharmaceutical manufacturer from Morocco and the wider Arab and African regions to receive GMP (Good Manufacturing Practice) certification. This prestigious certification, along with the necessary marketing authorizations, allows the company to market and sell its products within the expansive Eurasian bloc, facilitating the free movement of goods, services, capital, and labor among its member states. This achievement underscores the company's dedication to meeting international quality standards and regulatory compliance, which are crucial for competing in the global market.
Strategic Partnerships and Future Prospects
The successful shipment has been publicly confirmed by Russia’s trade representation in Morocco, which hails it as a pivotal step in Galenica’s strategy to penetrate the Eurasian market. This milestone is the culmination of years of rigorous efforts to align the company’s production processes with global standards. Established over four decades ago, Galenica has emerged as one of Morocco’s leading pharmaceutical manufacturers, and this new venture is expected to bolster its position on the international stage.
This export initiative is not just a commercial endeavor; it also revitalizes a partnership that began during the Covid-19 pandemic when Morocco granted emergency use authorization for Russia’s Sputnik V vaccine in March 2021. At that time, Russian officials recognized Morocco’s strategic position in Africa as a potential hub for broader vaccine distribution across the continent, with Galenica being suggested as a possible local manufacturer for the Russian vaccine.
Furthermore, this export aligns with Morocco's broader ambition to achieve pharmaceutical sovereignty. In a recent address in Nairobi, Head of Government Aziz Akhannouch emphasized significant reforms, including the expansion of health insurance coverage to 88% of the population and increased local drug production that meets over 70% of national needs. He articulated that health is now viewed as a matter of state security and sovereignty, rather than merely a social concern. This perspective is likely to drive further investments and innovations within the Moroccan pharmaceutical sector, positioning it as a key player in the global market.
As reported by northafricapost.com.
